The University of Chicago Header Logo

Connection

Christopher Daugherty to Female

Back to Details
This is a "connection" page, showing publications Christopher Daugherty has written about Female.
Christopher Daugherty
Connection Strength
0.468
Female
  1. Anxiety Shapes Expectations of Therapeutic Benefit in Phase I Trials for Patients With Advanced Cancer and Spousal Caregivers. JCO Oncol Pract. 2021 02; 17(2):e101-e110.
    View in: PubMed
    Score: 0.032
  2. Prevalence and Severity of Rationing During Drug Shortages: A National Survey of Health System Pharmacists. JAMA Intern Med. 2019 05 01; 179(5):710-711.
    View in: PubMed
    Score: 0.028
  3. Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials? J Clin Oncol. 2018 08 20; 36(24):2483-2491.
    View in: PubMed
    Score: 0.027
  4. Investigator Disclosure and Advanced Cancer Patient Understanding of Informed Consent and Prognosis in Phase I Clinical Trials. J Oncol Pract. 2018 06; 14(6):e357-e367.
    View in: PubMed
    Score: 0.027
  5. Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. Cancer. 2016 Mar 15; 122(6):954-61.
    View in: PubMed
    Score: 0.023
  6. The development of a financial toxicity patient-reported outcome in cancer: The COST measure. Cancer. 2014 Oct 15; 120(20):3245-53.
    View in: PubMed
    Score: 0.020
  7. Oncologists' and physiatrists' attitudes regarding rehabilitation for patients with advanced cancer. PM R. 2012 Feb; 4(2):96-108.
    View in: PubMed
    Score: 0.017
  8. When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response. Cancer. 2012 Jul 01; 118(13):3417-25.
    View in: PubMed
    Score: 0.017
  9. Parent opinions regarding the genetic testing of minors for BRCA1/2. J Clin Oncol. 2010 Jul 20; 28(21):3498-505.
    View in: PubMed
    Score: 0.015
  10. Physician preferences and knowledge gaps regarding the care of childhood cancer survivors: a mailed survey of pediatric oncologists. J Clin Oncol. 2010 Feb 10; 28(5):878-83.
    View in: PubMed
    Score: 0.015
  11. Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psychooncology. 2009 Feb; 18(2):200-8.
    View in: PubMed
    Score: 0.014
  12. What are terminally ill cancer patients told about their expected deaths? A study of cancer physicians' self-reports of prognosis disclosure. J Clin Oncol. 2008 Dec 20; 26(36):5988-93.
    View in: PubMed
    Score: 0.014
  13. An international pilot study of oncology physicians' opinions and practices on Complementary and Alternative Medicine (CAM). Integr Cancer Ther. 2008 Jun; 7(2):70-5.
    View in: PubMed
    Score: 0.013
  14. Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. Am J Med Genet C Semin Med Genet. 2008 Feb 15; 148C(1):70-7.
    View in: PubMed
    Score: 0.013
  15. How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol. 2007 Aug 20; 25(24):3705-11.
    View in: PubMed
    Score: 0.013
  16. Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials. J Clin Oncol. 2007 Aug 10; 25(23):3488-94.
    View in: PubMed
    Score: 0.013
  17. Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol. 2007 Feb 10; 25(5):548-54.
    View in: PubMed
    Score: 0.012
  18. Use of the internet to obtain cancer information among cancer patients at an urban county hospital. J Clin Oncol. 2005 Aug 01; 23(22):4954-62.
    View in: PubMed
    Score: 0.011
  19. Trusting God and medicine: spirituality in advanced cancer patients volunteering for clinical trials of experimental agents. Psychooncology. 2005 Feb; 14(2):135-46.
    View in: PubMed
    Score: 0.011
  20. American oncologists' views of internet use by cancer patients: a mail survey of American Society of Clinical Oncology members. J Clin Oncol. 2003 Mar 01; 21(5):942-7.
    View in: PubMed
    Score: 0.009
  21. Utilization of an Electronic Patient-Reported Outcome Platform to Evaluate the Psychosocial and Quality-of-Life Experience Among a Community Sample of Ovarian Cancer Survivors. JCO Clin Cancer Inform. 2022 08; 6:e2200035.
    View in: PubMed
    Score: 0.009
  22. Referral and decision making among advanced cancer patients participating in Phase I trials at a single institution. J Clin Ethics. 2001; 12(1):31-8.
    View in: PubMed
    Score: 0.008
  23. Before Consent: Qualitative Analysis of Deliberations of Patients With Advanced Cancer About Early-Phase Clinical Trials. JCO Oncol Pract. 2020 01; 16(1):e56-e63.
    View in: PubMed
    Score: 0.007
  24. Study of cohort-specific consent and patient control in phase I cancer trials. J Clin Oncol. 1998 Jul; 16(7):2305-12.
    View in: PubMed
    Score: 0.007
  25. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv. 2018 01 23; 2(2):146-150.
    View in: PubMed
    Score: 0.006
  26. What advanced cancer patients with limited treatment options know about clinical research: a qualitative study. Support Care Cancer. 2017 10; 25(10):3235-3242.
    View in: PubMed
    Score: 0.006
  27. Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST). Cancer. 2017 02 01; 123(3):476-484.
    View in: PubMed
    Score: 0.006
  28. Hope and the limits of research. Hastings Cent Rep. 1996 Sep-Oct; 26(5):20; discussion 20-2.
    View in: PubMed
    Score: 0.006
  29. Interest in initiating an early phase clinical trial: results of a longitudinal study of advanced cancer patients. Psychooncology. 2017 Oct; 26(10):1604-1610.
    View in: PubMed
    Score: 0.006
  30. An Evaluation of Psychosocial and Religious Belief Differences in a Diverse Racial and Socioeconomic Urban Cancer Population. J Racial Ethn Health Disparities. 2017 04; 4(2):140-148.
    View in: PubMed
    Score: 0.006
  31. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995 May; 13(5):1062-72.
    View in: PubMed
    Score: 0.005
  32. Human subjects protection: an event monitoring committee for research studies of girls from breast cancer families. J Adolesc Health. 2014 Sep; 55(3):352-7.
    View in: PubMed
    Score: 0.005
  33. General internists' preferences and knowledge about the care of adult survivors of childhood cancer: a cross-sectional survey. Ann Intern Med. 2014 Jan 07; 160(1):11-7.
    View in: PubMed
    Score: 0.005
  34. Family physician preferences and knowledge gaps regarding the care of adolescent and young adult survivors of childhood cancer. J Cancer Surviv. 2013 Sep; 7(3):275-82.
    View in: PubMed
    Score: 0.005
  35. Physician preferences and knowledge regarding the care of childhood cancer survivors in Japan: a mailed survey of the Japanese Society of Pediatric Oncology. Jpn J Clin Oncol. 2012 Jun; 42(6):513-21.
    View in: PubMed
    Score: 0.004
  36. High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML). Leuk Lymphoma. 2012 Mar; 53(3):445-50.
    View in: PubMed
    Score: 0.004
  37. Treatment of therapy-related myeloid neoplasms with high-dose cytarabine/mitoxantrone followed by hematopoietic stem cell transplant. Leuk Lymphoma. 2010 Jun; 51(6):995-1006.
    View in: PubMed
    Score: 0.004
  38. Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2007 Dec; 40(11):1027-32.
    View in: PubMed
    Score: 0.003
  39. Performance status and comorbidity predict transplant-related mortality after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2006 Sep; 12(9):954-64.
    View in: PubMed
    Score: 0.003
  40. Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005 Aug 20; 23(24):5728-38.
    View in: PubMed
    Score: 0.003
  41. Biologic effects of prolonged melphalan treatment of murine long-term bone marrow cultures and interleukin 3-dependent hematopoietic progenitor cell lines. J Natl Cancer Inst. 1985 Jan; 74(1):247-62.
    View in: PubMed
    Score: 0.003
  42. A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. Cancer Chemother Pharmacol. 2004 Dec; 54(6):553-61.
    View in: PubMed
    Score: 0.003
  43. Psychosocial adjustment of patients and caregivers prior to allogeneic bone marrow transplantation. Bone Marrow Transplant. 2001 Jun; 27(11):1181-8.
    View in: PubMed
    Score: 0.002
  44. Preliminary experience with a new chemotherapy regimen for adults with acute lymphoblastic leukemia. Leuk Lymphoma. 2001 Apr; 41(3-4):297-307.
    View in: PubMed
    Score: 0.002
  45. A dose escalation study of total body irradiation followed by high-dose etoposide and allogeneic blood stem cell transplantation for the treatment of advanced hematologic malignancies. Bone Marrow Transplant. 2000 Apr; 25(8):807-13.
    View in: PubMed
    Score: 0.002
  46. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: a pilot study. J Clin Endocrinol Metab. 1998 Aug; 83(8):2717-25.
    View in: PubMed
    Score: 0.002
  47. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant. 1997 Sep; 20(5):369-74.
    View in: PubMed
    Score: 0.002
  48. Prognostic factors for functional outcome of total knee replacement: a prospective study. J Gerontol A Biol Sci Med Sci. 1996 Jul; 51(4):M152-7.
    View in: PubMed
    Score: 0.001
  49. Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst. 1994 Nov 16; 86(22):1685-93.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.